NCT05924997View on ClinicalTrials.gov

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

adebrelimab, camrelizumab plus apatinib

adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle

Trial Locations (1)

510220

RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER